Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single dose pharmacokinetic study of HP-3060 in pediatric patients with allergic rhinitis (2)
jRCT2080223788Phase 2Completed
- Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of emedastine in allergic rhinitis (AR), sponsored by Hisamitsu Pharmaceutical Co., Inc. Primary endpoint: Pharmacokinetics of emedastine after single transdermal dose. Started Jan 2018; status: completed.
02
Drugs
emedastine
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on jRCT2080223788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223788.